Findings

What do systematic reviews say?

21 questions · 21 findings · 1 reviews · Vascular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 19%GRADE not reported 0 · 0%Very low 0 · 0%Low 8 · 38.1%Moderate 9 · 42.9%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Anticoagulant vs placebo or no treatment · Need for hospitalisation
  Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
  RR 1.01 [0.59, 1.75]
  4 studies · 1459 participants
  Moderate
Direct match · question page
- Anticoagulant vs placebo or no treatment · Venous thromboembolism
  Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
  RR 0.36 [0.16, 0.85]
  4 studies · 1259 participants
  Moderate
Direct match · question page
- Anticoagulant vs placebo or no treatment · Pulmonary embolism
  Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
  RR 0.25 [0.08, 0.79]
  3 studies · 1009 participants
  Moderate
Direct match · question page
- Anticoagulant vs placebo or no treatment · Deep vein thrombosis
  Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
  RR 1.02 [0.3, 3.46]
  3 studies · 1009 participants
  Moderate
Direct match · question page
- Anticoagulant vs different dose of the same anticoagulant · Need for hospitalisation
  Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
  RR 1.89 [0.17, 20.58]
  1 study · 278 participants
  Low

Anticoagulant vs placebo or no treatment

All‐cause mortality · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.36 [0.04, 3.61]
5 studies · 1777 participants
Low

Anticoagulant vs different dose of the same anticoagulant

Major bleeding · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 278 participants
Moderate

Anticoagulant vs different dose of the same anticoagulant

Deep vein thrombosis · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anticoagulant vs different dose of the same anticoagulant

Pulmonary embolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anticoagulant vs different dose of the same anticoagulant

Need for hospitalisation · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in need for hospitalisation compared with different dose of the same anticoagulant (low certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 1.89 [0.17, 20.58]
1 study · 278 participants
Low

Anticoagulant vs different dose of the same anticoagulant

Adverse events (minor bleeding) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in adverse events (minor bleeding) compared with different dose of the same anticoagulant (low certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.47 [0.09, 2.54]
1 study · 278 participants
Low

Anticoagulant vs antiplatelet agent

All‐cause mortality · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 279 participants
Moderate

Anticoagulant vs antiplatelet agent

Venous thromboembolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in venous thromboembolism compared with antiplatelet agent (low certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.36 [0.01, 8.65]
1 study · 279 participants
Low

Anticoagulant vs antiplatelet agent

Major bleeding · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 279 participants
Moderate

Anticoagulant vs antiplatelet agent

Deep vein thrombosis · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anticoagulant vs antiplatelet agent

Pulmonary embolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anticoagulant vs placebo or no treatment

Venous thromboembolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant probably leads to lower venous thromboembolism compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.36 [0.16, 0.85]
4 studies · 1259 participants
Moderate

Anticoagulant vs antiplatelet agent

Need for hospitalisation · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in need for hospitalisation compared with antiplatelet agent (low certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 3.2 [0.13, 77.85]
1 study · 279 participants
Low

Anticoagulant vs antiplatelet agent

Adverse events (minor bleeding) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in adverse events (minor bleeding) compared with antiplatelet agent (low certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 2.13 [0.4, 11.46]
1 study · 279 participants
Low

Anticoagulant vs placebo or no treatment

Major bleeding · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in major bleeding compared with placebo or no treatment (low certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.36 [0.01, 8.78]
5 studies · 1777 participants
Low

Anticoagulant vs placebo or no treatment

Deep vein thrombosis · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in deep vein thrombosis compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 1.02 [0.3, 3.46]
3 studies · 1009 participants
Moderate

Anticoagulant vs placebo or no treatment

Pulmonary embolism · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant probably leads to lower pulmonary embolism compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 0.25 [0.08, 0.79]
3 studies · 1009 participants
Moderate

Anticoagulant vs placebo or no treatment

Need for hospitalisation · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in need for hospitalisation compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 1.01 [0.59, 1.75]
4 studies · 1459 participants
Moderate

Anticoagulant vs placebo or no treatment

Adverse events (minor bleeding) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Anticoagulant showed no clear difference in adverse events (minor bleeding) compared with placebo or no treatment (low certainty).

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
RR 2.46 [0.9, 6.72]
5 studies · 1777 participants
Low

Anticoagulant vs different dose of the same anticoagulant

All‐cause mortality · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

1 finding from 1 review

Prophylactic anticoagulants for non‐hospitalised people with COVID‐19 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 278 participants
Moderate